Variance Ranking for Multi-Classed Imbalanced Datasets: A Case Study of One-Versus-All

Imbalanced classes in multi-classed datasets is one of the most salient hindrances to the accuracy and dependable results of predictive modeling. In predictions, there are always majority and minority classes, and in most cases it is difficult to capture the members of item belonging to the minority classes. This anomaly is traceable to the designs of the predictive algorithms because most algorithms do not factor in the unequal numbers of classes into their designs and implementations. The accuracy of most modeling processes is subjective to the ever-present consequences of the imbalanced classes. This paper employs the variance ranking technique to deal with the real-world class imbalance problem. We augmented this technique using one-versus-all re-coding of the multi-classed datasets. The proof-of-concept experimentation shows that our technique performs better when compared with the previous work done on capturing small class members in multi-classed datasets

High sensitivity C-Reactive Protein is a Significant Predictor for Hypertension and Obesity in Iraqi Postmenopausal Women

Background: several new inflammatory markers have emerged as strong predictors of cardiovascular disease in healthy and non-healthy subjects, one of these markers is hs-CRP, which has been proposed as independent risk factor for cardiovascular disease, and it is positively associated with body weight. Little is known, however, about the utility of hs-CRP and other biomarkers in obese hypertensive Iraqi post menopausal women.The aim of study is to examine the hypothesis that there is a relation between obesity, hypertension and a chronic low-grade inflammatory status (represented by high hs-CRP). Patients and Methods: A total number of 99 postmenopausal women classified into obese hypertensive group (case) and non obese non hypertensive group(control). For these groups, measurement of zinc, calcium, phosphorus, lipid profile, High sensitivity C–Reactive Protein, body mass index and waist circumference were done. Results: The (Mean ± SD) of hs-CRP in the cases and controls were (5.74 ± 2.1) mg/land (2.1 ± 0.8) mg/l respectively, (P 0,05) while body mass index , waist circumference ,HDL ,LDL ,and total were statistically significant (Pvalue <0,05). Conclusion: There is an elevated serum level of hs-CRP in hypertensive and obese subjects in comparison with low levels in control group (non obese non hypertensive) which suggest a role of hs- CRP in developing hypertension and obesity

Policy-Based Security Management System for 5G Heterogeneous Networks

Advances in mobile phone technology and the growth of associated networks have been phenomenal over the last decade. Therefore, they have been the focus of much academic research, driven by commercial and end-user demands for increasingly faster technology. The most recent generation of mobile network technology is the fifth generation (5G). 5G networks are expected to launch across the world by 2020 and to work with existing 3G and 4G technologies to provide extreme speed despite being limited to wireless technologies. An alternative network, Y-Communication (Y-Comm), proposes to integrate the current wired and wireless networks, attempting to achieve the main service requirements of 5G by converging the existing networks and providing an improved service anywhere at any time. Quality of service (QoS), vertical handover, and security are some of the technical concerns resulting from this heterogeneity. In addition, it is believed that the Y-Comm convergence will have a greater influence on security than was the case with the previous long-term evolution (LTE) 4G networks and with future 5G networks. The purpose of this research is to satisfy the security recommendations for 5G mobile networks. This research provides a policy-based security management system, ensuring that end-user devices cannot be used as weapons or tools of attack, for example, IP spoofing and man-in-the-middle (MITM) attacks. The results are promising, with a low disconnection rate of less than 4% and 7%. This shows the system to be robust and reliable

From Conventional to State-of-the-Art IoT Access Control Models

open access articleThe advent in Online Social Networks (OSN) and Internet of Things (IoT) has created a new world of collaboration and communication between people and devices. The domain of internet of things uses billions of devices (ranging from tiny sensors to macro scale devices) that continuously produce and exchange huge amounts of data with people and applications. Similarly, more than a billion people are connected through social networking sites to collaborate and share their knowledge. The applications of IoT such as smart health, smart city, social networking, video surveillance and vehicular communication are quickly evolving people’s daily lives. These applications provide accurate, information-rich and personalized services to the users. However, providing personalized information comes at the cost of accessing private information of users such as their location, social relationship details, health information and daily activities. When the information is accessible online, there is always a chance that it can be used maliciously by unauthorized entities. Therefore, an effective access control mechanism must be employed to ensure the security and privacy of entities using OSN and IoT services. Access control refers to a process which can restrict user’s access to data and resources. It enforces access rules to grant authorized users an access to resources and prevent others. This survey examines the increasing literature on access control for traditional models in general, and for OSN and IoT in specific. Challenges and problems related to access control mechanisms are explored to facilitate the adoption of access control solutions in OSN and IoT scenarios. The survey provides a review of the requirements for access control enforcement, discusses several security issues in access control, and elaborates underlying principles and limitations of famous access control models. We evaluate the feasibility of current access control models for OSN and IoT and provide the future development direction of access control for the sam

Amyotrophic lateral sclerosis transcriptomics reveals immunological effects of low-dose interleukin-2

Amyotrophic lateral sclerosis is a fatal neurodegenerative disease causing upper and lower motor neuron loss and currently no effective disease-modifying treatment is available. A pathological feature of this disease is neuroinflammation, a mechanism which involves both CNS-resident and peripheral immune system cells. Regulatory T-cells are immune-suppressive agents known to be dramatically and progressively decreased in patients with amyotrophic lateral sclerosis. Low-dose interleukin-2 promotes regulatory T-cell expansion and was proposed as an immune-modulatory strategy for this disease. A randomized placebo-controlled pilot phase-II clinical trial called Immuno-Modulation in Amyotrophic Lateral Sclerosis was carried out to test safety and activity of low-dose interleukin-2 in 36 amyotrophic lateral sclerosis patients (NCT02059759). Participants were randomized to 1MIU, 2MIU-low-dose interleukin-2 or placebo and underwent one injection daily for 5 days every 28 days for three cycles. In this report, we describe the results of microarray gene expression profiling of trial participants' leukocyte population. We identified a dose-dependent increase in regulatory T-cell markers at the end of the treatment period. Longitudinal analysis revealed an alteration and inhibition of inflammatory pathways occurring promptly at the end of the first treatment cycle. These responses are less pronounced following the end of the third treatment cycle, although an activation of immune-regulatory pathways, involving regulatory T-cells and T helper 2 cells, was evident only after the last cycle. This indicates a cumulative effect of repeated low-dose interleukin-2 administration on regulatory T-cells. Our analysis suggested the existence of inter-individual variation amongst trial participants and we therefore classified patients into low, moderate and high-regulatory T-cell-responders. NanoString profiling revealed substantial baseline differences between participant immunological transcript expression profiles with the least responsive patients showing a more inflammatory-prone phenotype at the beginning of the trial. Finally, we identified two genes in which pre-treatment expression levels correlated with the magnitude of drug responsiveness. Therefore, we proposed a two-biomarker based regression model able to predict patient regulatory T-cell-response to low-dose interleukin-2. These findings and the application of this methodology could be particularly relevant for future precision medicine approaches to treat amyotrophic lateral sclerosis

Changes of tau profiles in brains of the hamsters infected with scrapie strains 263 K or 139 A possibly associated with the alteration of phosphate kinases

<p>Abstract</p> <p>Background</p> <p>Phospho-tau deposition has been described in a rare genetic human prion disease, Gerstmann-Sträussler-Scheinker syndrome, but is not common neuropathological picture for other human and animal transmissible spongiform encephalopathies (TSEs). This study investigated the possible changes of tau and phosphorylated tau (p-tau, at Ser396, Ser404, and Ser202/Thr205) in scrapie experimental animals.</p> <p>Methods</p> <p>The profiles of tau and p-tau (p-tau, at Ser396, Ser404, and Ser202/Thr205) in the brain tissues of agents 263K- or 139A-infected hamsters were evaluated by Western blots and real-time PCR. Meanwhile, the transcriptional and expressive levels of GSK3β and CDK5 in the brains were tested.</p> <p>Results</p> <p>The contents of total tau and p-tau at Ser202/Thr205 increased, but p-tau at Ser396 and Ser404 decreased at the terminal stages, regardless of scrapie strains. Transcriptional levels of two tau isoforms were also increased. Additionally, it showed higher CDK5, but lower GSK3β transcriptional and expressive levels in the brains of scrapie-infected animals. Analysis of brain samples collected from different times after inoculated with agent 263 K revealed that the changes of tau profiles and phosphate kinases were time-relative events.</p> <p>Conclusion</p> <p>These data suggest that changes of profiles of p-tau at Ser396, Ser404 and Ser202/Thr205 are illness-correlative phenomena in TSEs, which may arise of the alteration of phosphate kinases. Alteration of tau, p-tau (Ser396, Ser404, and Ser202/Thr205), GSK3β and CDK5 were either intermediate or consequent events in TSE pathogenesis and proposed the potential linkage of these bioactive proteins with the pathogenesis of prion diseases.</p

Interaction between CRHR1 and BDNF Genes Increases the Risk of Recurrent Major Depressive Disorder in Chinese Population

BACKGROUND: An important etiological hypothesis about depression is stress has neurotoxic effects that damage the hippocampal cells. Corticotropin-releasing hormone (CRH) regulates brain-derived neurotrophic factor (BDNF) expression through influencing cAMP and Ca2+ signaling pathways during the course. The aim of this study is to examine the single and combined effects of CRH receptor 1 (CRHR1) and BDNF genes in recurrent major depressive disorder (MDD). METHODOLOGY/PRINCIPAL FINDING: The sample consists of 181 patients with recurrent MDD and 186 healthy controls. Whether genetic variations interaction between CRHR1 and BDNF genes might be associated with increased susceptibility to recurrent MDD was studied by using a gene-based association analysis of single-nucleotide polymorphisms (SNPs). CRHR1 gene (rs1876828, rs242939 and rs242941) and BDNF gene (rs6265) were identified in the samples of patients diagnosed with recurrent MDD and matched controls. Allelic association between CRHR1 rs242939 and recurrent MDD was found in our sample (allelic: p = 0.018, genotypic: p = 0.022) with an Odds Ratio 0.454 (95% CI 0.266-0.775). A global test of these four haplotypes showed a significant difference between recurrent MDD group and control group (chi-2 = 13.117, df = 3, P = 0.016. Furthermore, BDNF and CRHR1 interactions were found in the significant 2-locus, gene-gene interaction models (p = 0.05) using a generalized multifactor dimensionality reduction (GMDR) method. CONCLUSION: Our results suggest that an interaction between CRHR1 and BDNF genes constitutes susceptibility to recurrent MDD

The application of cortical layer markers in the evaluation of cortical dysplasias in epilepsy

The diagnostic criteria for focal cortical dysplasia type I (FCD I) remain to be well and consistently defined. Cortical layer-specific markers (CLM) provide a potential tool for the objective assessment of any dyslamination. We studied expression patterns of recognised CLM using immunohistochemistry for N200, ER81, Otx1, Map1b (subsets of V/VI projection neurones), Pax6, Tbr1, Tbr2 (differentially expressed in cortical neurones from intermediate progenitor cells), Cux 1 (outer cortical layers) and MASH1 (ventricular zone progenitors). Dysplasia subtypes included FCD I and II, dysplasias adjacent to hippocampal sclerosis (HS) or dysembryoplastic neuroepithelial tumours (DNTs); all were compared to neonatal and adult controls. Laminar expression patterns in normal cortex were observed with Tbr1, Map1b, N200 and Otx1. FCDI cases in younger patients were characterised by abnormal expression in layer II for Tbr1 and Otx1. FCDII showed distinct labelling of balloon cells (Pax6, ER81 and Otx1) and dysmorphic neurones (Tbr 1, N200 and Map1b) supporting origins from radial glia and intermediate progenitor cells, respectively. In temporal lobe sclerosis cases with dysplasia adjacent to HS, Tbr1 and Map1b highlighted abnormal orientation of neurones in layer II. Dyslamination was not confirmed in the perilesional cortex of DNT with CLM. Finally, immature cell types (Otx1, Pax6 and Tbr2) were noted in varied pathologies. One possibility is activation of progenitor cell populations which could contribute to the pathophysiology of these lesions

Ablation of NG2 Proteoglycan Leads to Deficits in Brown Fat Function and to Adult Onset Obesity

Obesity is a major health problem worldwide. We are studying the causes and effects of obesity in C57Bl/6 mice following genetic ablation of NG2, a chondroitin sulfate proteoglycan widely expressed in progenitor cells and also in adipocytes. Although global NG2 ablation delays early postnatal adipogenesis in mouse skin, adult NG2 null mice are paradoxically heavier than wild-type mice, exhibiting larger white fat deposits. This adult onset obesity is not due to NG2-dependent effects on CNS function, since specific ablation of NG2 in oligodendrocyte progenitors yields the opposite phenotype; i.e. abnormally lean mice. Metabolic analysis reveals that, while activity and food intake are unchanged in global NG2 null mice, O2 consumption and CO2 production are decreased, suggesting a decrease in energy expenditure. Since brown fat plays important roles in regulating energy expenditure, we have investigated brown fat function via cold challenge and high fat diet feeding, both of which induce the adaptive thermogenesis that normally occurs in brown fat. In both tests, body temperatures in NG2 null mice are reduced compared to wild-type mice, indicating a deficit in brown fat function in the absence of NG2. In addition, adipogenesis in NG2 null brown pre-adipocytes is dramatically impaired compared to wild-type counterparts. Moreover, mRNA levels for PR domain containing 16 (PRDM16) and peroxisome proliferator-activated receptor γ coactivator (PGC)1-α, proteins important for brown adipocyte differentiation, are decreased in NG2 null brown fat deposits in vivo and NG2 null brown pre-adipocytes in vitro. Altogether, these results indicate that brown fat dysfunction in NG2 null mice results from deficits in the recruitment and/or development of brown pre-adipocytes. As a consequence, obesity in NG2 null mice may occur due to disruptions in brown fat-dependent energy homeostasis, with resulting effects on lipid storage in white adipocytes

Amyotrophic lateral sclerosis transcriptomics reveals immunological effects of low-dose interleukin-2

Amyotrophic lateral sclerosis is a fatal neurodegenerative disease causing upper and lower motor neuron loss and currently no effective disease-modifying treatment is available. A pathological feature of this disease is neuroinflammation, a mechanism which involves both CNS-resident and peripheral immune system cells. Regulatory T-cells are immune-suppressive agents known to be dramatically and progressively decreased in patients with ALS. Low-dose interleukin-2 promotes regulatory T-cell expansion and was proposed as an immune-modulatory strategy for this disease. A randomized placebo-controlled pilot phase-II clinical trial called Immuno-Modulation in Amyotrophic Lateral Sclerosis (IMODALS) was carried out to test safety and activity of low-dose interleukin-2 in 36 amyotrophic lateral sclerosis patients (NCT02059759). Participants were randomized to 1MIU, 2MIU-low-dose interleukin-2 or placebo and underwent one injection daily for five days every twenty-eight days for three cycles. In this report, we describe the results of microarray gene expression profiling of trial participants' leukocyte population. We identified a dose-dependent increase in regulatory T-cell markers at the end of the treatment period. Longitudinal analysis revealed an alteration and inhibition of inflammatory pathways occurring promptly at the end of the first treatment cycle. These responses are less pronounced following the end of the third treatment cycle, although an activation of immune-regulatory pathways, involving regulatory T-cells and T helper 2 cells, was evident only after the last cycle. This indicates a cumulative effect of repeated low-dose interleukin-2 administration on regulatory T-cells. Our analysis suggested the existence of inter-individual variation amongst trial participants and we therefore classified patients into low, moderate and high-Treg-responders. NanoString profiling revealed substantial baseline differences between participant immunological transcript expression profiles with the least responsive patients showing a more inflammatory-prone phenotype at the beginning of the trial. Finally, we identified two genes in which pre-treatment expression levels correlated with the magnitude of drug responsiveness. Therefore, we proposed a two-biomarker based regression model able to predict patient Treg-response to low-dose interleukin-2. These findings and the application of this methodology could be particularly relevant for future precision medicine approaches to treat amyotrophic lateral sclerosis